secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122342
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics reports Q3 net loss of $25.6M; DSMB clears dose escalation for TN-201 gene therapy
--------------------------------------------------------------------------------

- Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.
- Cash and investments $79.5M; runway expected into H2 2025.
- DSMB recommended dose escalation to 6E13 vg/kg for TN-201 in MyPEAK-1; initial Cohort 1 data expected Dec 2024.
- Expanded MyPEAK-1 eligibility to include obstructive HCM patients and those without ICDs; baseline biopsy added.
- Entered $45M undrawn credit facility with Silicon Valley Bank in August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024122342/0000950170-24-122342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024122342/tnya-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer